RotaTeq

RSS

rotavirus vaccine, live

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR) for RotaTeq. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for RotaTeq.

This EPAR was last updated on 07/12/2018

Authorisation details

Product details
Name
RotaTeq
Agency product number
EMEA/H/C/000669
Active substance
rotavirus serotype G1, serotype G2, serotype G3, serotype G4, serotype P1
International non-proprietary name (INN) or common name
rotavirus vaccine, live
Therapeutic area (MeSH)
  • Immunization
  • Rotavirus Infections
Anatomical therapeutic chemical (ATC) code
J07BH02
Publication details
Marketing-authorisation holder
MSD VACCINS
Revision
27
Date of issue of marketing authorisation valid throughout the European Union
26/06/2006
Contact address
162 avenue Jean Jaurès
69007 Lyon
France

Product information

21/05/2018 RotaTeq - EMEA/H/C/000669 - IB/0076

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

VIRAL VACCINES

Therapeutic indication

RotaTeq is indicated for the active immunisation of infants from the age of six weeks to 32 weeks for prevention of gastroenteritis due to rotavirus infection.

RotaTeq is to be used on the basis of official recommendations.

Assessment history

Changes since initial authorisation of medicine

How useful was this page?

Add your rating